The financials
Rhythm Pharmaceuticals, Inc. by the numbers
Rhythm Pharmaceuticals, Inc. (RYTM) reported revenue of $71M in Q2 2026 (quarter ended June 30, 2026), up 47% from the same quarter a year earlier. That came with a gross margin of 87% and net loss of $49M. For the full year FY2025, revenue was $190M (+46% year on year) and net income −$197M. Its largest region in 2026-Q1 was US at $37M, 61% of the disclosed total, just ahead of Non Us at 39%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $71M | $49M | +47% |
| Gross profit | $62M | $43M | +45% |
| Operating income | −$49M | −$45M | n/a |
| Net income | −$49M | −$47M | n/a |
| Diluted EPS | −$0.73 | −$0.75 | n/a |
| Geographic | Revenue | Share |
|---|---|---|
| US | $37M | 61% |
| Non Us | $23M | 39% |
Business Segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Q1 2026Total $60.1M (+17%)
Non Us grew +74% year on yearUS +51% year on year
Segment Latestquarter on quarteryear on year
- US$36.9M$36.9MQoQ -3.4%year on year +51%-3.4%+51%
- Non Us$23.2M$23.2MQoQ +77%year on year +74%+77%+74%